Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02771977 · ClinicalTrials.gov registry record · NA
Drug-Targeted Alerts for Acute Kidney Injury
A NA study, sponsored by Yale University.
- Completed
- Registry status
- NA
- Development phase
- 5,060
- Enrollment target
NCT02771977: Completed NA study, sponsored by Yale University.
NCT02771977 is a NA study that has completed, run by Yale University. The registered enrollment target is 5,060 participants, above the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (260% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02771977, a NA study, has completed, sponsored by Yale University.
- COMPLETED
- Registry status
- NA
- Development phase
- 5,060 participants
- Enrollment target
Study Summary
In this trial, patients with acute kidney injury who have recently received a drug that may affect kidney function will be randomized to having an alert placed in the electronic health record or usual care.
Primary Outcome
Progression of AKI is defined by an increase in KDIGO creatinine stage from time of randomization to the present. Dialysis is defined by the receipt of hemodialysis, continuous renal replacement therapy or peritoneal dialysis. Isolated ultrafiltration treatments will not be included. Mortality will be determined from hospital records.
Interventions
- OTHER Drug-specific alert
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5,060 participants |
| Start Date | 2020-08-24 |
| Est. Completion | 2022-01-04 |
| Phase | NA |
What the finished NCT02771977 record still lists
NCT02771977 is an interventional study that assigns participants to a tested intervention. Its 5,060 participants enrollment target places it among the larger protocols in the corpus, above the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (260% higher).
The record links to 0 conditions, and to 1 intervention - of which Drug-specific alert is the first listed.
NCT02771977 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02771977 about?
NCT02771977 is a clinical study titled "Drug-Targeted Alerts for Acute Kidney Injury". In this trial, patients with acute kidney injury who have recently received a drug that may affect kidney function will be randomized to having an alert placed in the electronic health record or usual care.
What is the current status of trial NCT02771977?
This trial is currently completed. It is a NA study. The enrollment target is 5,060 participants. The study started on 2020-08-24. Estimated completion is 2022-01-04.
What interventions are being tested in trial NCT02771977?
The interventions under investigation include: Drug-specific alert (OTHER).
Who is sponsoring clinical trial NCT02771977?
This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02771977's enrollment target sits among peer trials
5,060 25th of 2000 higher than 1,976 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT07037459 · 5,056 participants · Phase 3
Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity
- NCT06292078 · 5,076 participants · NA
Preventing School Exclusion and Opioid Misuse: Effectiveness of the Inclusive Skill-building Learning Approach (ISLA)
- NCT05018611 · 5,100 participants · NA
Digital Limited Interaction Efficacy Trial of LifeSkills Mobile to Reduce HIV Incidence in YTW
- NCT05701358 · 5,100 participants · NA
Physiology-guided vs Angiography-guided Non-culprit Lesion Complete Revascularization for Acute MI & Multivessel Disease
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI